Compare ITP & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | VRAX |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2020 | 2021 |
| Metric | ITP | VRAX |
|---|---|---|
| Price | $0.15 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 222.9K | 155.7K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,837,943.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.13 | $0.10 |
| 52 Week High | $0.39 | $13.19 |
| Indicator | ITP | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 32.74 |
| Support Level | $0.13 | $0.16 |
| Resistance Level | $0.20 | $3.01 |
| Average True Range (ATR) | 0.01 | 0.27 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 42.50 | 4.49 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.